Minova Life Science

Minova life sciences - Pharmaceutical company

Tofadac 5

Turning the Tide on RA


Composition: Tofacitinib 5 mg


  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Ulcerative Colitis


Drug class: Janus kinase (JAK) inhibitors

  • Useful option for the treatment of adult patients with moderate to severe RA
  • Is efficacious and has a manageable safety profile in patients who are negatively responding to DMARDs, DMARD MTX, or TNF inhibitors.
  • Its monotherapy inhibited the progression of structural damage in methotrexate-naïve patients during ≤ 24 months’ treatment.
  • Its tolerability profile was generally similar to that of biological DMARDs

Explore other products

Scroll to Top